Journal: bioRxiv
Article Title: Akr1d1-/- mice have a sexually dimorphic metabolic phenotype with reduced fat mass, increased insulin sensitivity and hypertriglyceridemia in males
doi: 10.1101/2021.02.02.429227
Figure Lengend Snippet: Akr1d1 deletion (A: western blot, liver), does not alter serum corticosterone levels (B) (n = 10 mice), or hepatic mRNA expression of glucocorticoid responsive genes, Sgk1, Gilz, Dusp1 and 11 β hsd1 (C) (n = 10 mice). Male and female Akr1d1-/- mice have decreased total hepatic (D) and serum (E) bile acids and altered bile acid composition with reduced 12α-hydroxylated/non-12α-hydroxylated bile ratio in the liver (F & G) and serum (H & I) (n = 12-15 mice). Principle Component Analysis shows greater divergence from wildtype in male Akr1d1-/- mice (J). Akr1d1 deletion has a sexually dimorphic effect on mRNA expression of hepatic bile acid metabolizing genes and levels of bile acid intermediates. Cyp8b1 expression is increased in Akr1d1-/- females but not males (K) (n = 10 mice) as are the AKR1D1 substrates 7α,12α-dihydroxy-4-chol-3-one (L) and 7α-hydroxy-4-chol-3-one (M) (n = 10 mice). The oxysterol 27-hydroxycholesterol (27-OHC) is decreased in Akr1d1-/- females (N) (n = 10 mice). Female Akr1d1-/- mice also have increased expression of the bile acid detoxifying genes Cyp3a11, Cyp2c55, Cyp4a12a and Sult2a7 (O) (n = 10 mice) and serum levels of LCA sulfate (P) (n = 10 mice). Data are presented as mean±se, log2(FC), ratio, or mean relative abundance. *p<0.05, * *p<0.01, * * *p<0.005, Ø p<0.001, ØØ p< 0.0005, ØØØ p<0.0001 compared to wildtype. mRNA expression was measured by RNASeq. p-values for bile acid composition compare WT and Akr1d1-/- within sex (male/female). (WT = wildtype C57BL/6; -/-= Akr1d1-/- )
Article Snippet: Principal component analysis was performed using the FactoMineR package and the factoextra package to visualise the results in R. Free and esterified oxysterols were measured as previously described with the following modifications: Liver (100 mg) was spiked with 30 μl of 1 μM internal standard mix 25(R/S), 26-Hydroxycholesterol-d4, 7α-hydroxy-4-cholesten-3-one-d7, 7α,12α-dihydroxycholest-4-en-3-one-d7) (Toronto Research Chemicals, Ontario, Canada) and homogenized in chloroform/methanol (4 ml: CHCl3/MeOH, 2:1, v/v) containing 50 μg/mL butylated hydroxytoluene.
Techniques: Western Blot, Expressing